What can replace Cosentyx (secukinumab)?
Cosentyx is a biologic drug used for several inflammatory conditions, including plaque psoriasis and psoriatic arthritis (among other indications). A “substitute” can mean either:
- another biologic with a different target, or
- a different therapy class (often a conventional systemic drug), depending on your diagnosis and how well you’ve responded.
The right substitute depends on what condition you’re treating, your prior treatments, and your insurance coverage.
Are there biosimilars for Cosentyx?
Yes—Cosentyx has biosimilar competition in some markets, but availability and timing vary by country and by specific presentation. If you tell me your country (and whether you’re using the 150 mg or 300 mg pen/syringe, if applicable), I can narrow the options to what’s actually available where you live.
What are the main alternative biologic targets if Cosentyx doesn’t work?
If Cosentyx doesn’t provide enough control, clinicians commonly switch within the biologic class or switch to another pathway. Common alternatives include:
- IL-17 pathway blockers (another agent in the same cytokine family)
- IL-12/23 or IL-23 pathway inhibitors
- TNF inhibitors
- (for some patients) other targeted immune therapies
Which one is most appropriate depends on your condition and history (for example, whether you’ve already tried an IL-17 drug).
What substitutes are used for plaque psoriasis specifically?
For plaque psoriasis, substitutes often include other systemic options such as:
- other biologics targeting IL-17, IL-23, or IL-12/23
- TNF inhibitors
- oral systemics or phototherapy when biologics aren’t suitable
Your dermatologist usually picks based on disease severity, comorbidities, and prior response.
What substitutes are used for psoriatic arthritis?
For psoriatic arthritis, substitutes are also typically biologics, with choices guided by whether you have:
- joint-predominant disease,
- skin symptoms,
- enthesitis/dactylitis,
- or axial involvement.
Switching is often considered when Cosentyx doesn’t control symptoms adequately or side effects occur.
If you want a cheaper substitute, what options typically reduce cost?
Cost-related substitutes usually come from one of these routes:
- switching to an available biosimilar (if applicable in your country)
- changing to a different biologic that your insurer prefers
- using an alternative coverage pathway (for example, prior authorization criteria)
- (sometimes) using a non-biologic systemic or other regimen if appropriate
For detailed product-by-product patent/exclusivity tracking, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/patent/ (you can search there for secukinumab/Cosentyx to see competition and timeline details).
What if you recently started Cosentyx—can you switch right away?
Switching too early can miss the chance for adequate response. Clinicians typically assess response after a defined trial period, then decide whether to:
- continue,
- dose-adjust (where applicable),
- or switch to another therapy.
If you share how long you’ve been on Cosentyx and what dose schedule you use, I can help map that to what questions doctors commonly ask next.
Tell me these 3 details and I’ll give targeted substitute options
1) Which condition are you treating (psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, hidradenitis suppurativa, or something else)?
2) What country are you in?
3) Have you tried any other biologics before (and which ones)?
Sources:
- [1] https://www.drugpatentwatch.com/patent/ (search for Cosentyx/“secukinumab” to check biosimilar/competition and timeline information)